Evidence map›Paper›PMID 31995749›Full record

ArticleCell reports2020

Regulatory T Cells Condition Lymphatic Endothelia for Enhanced Transendothelial Migration.

Wenji Piao, Yanbao Xiong, Lushen Li, Vikas Saxena, Kile D Smith, Keli L Hippen, Christina Paluskievicz, Marina Willsonshirkey, Bruce R Blazar, Reza Abdi and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Review
  3. Regulatory T cell and endothelial cell crosstalk.Nature reviews. Immunology · 2025
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Lymphotoxin limits Foxp3Nature communications · 2024
    Article
  11. Article
  12. Treg-tissue cell interactions in repair and regeneration.The Journal of experimental medicine · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Wenji PiaoCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Yanbao XiongCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Lushen LiCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Vikas SaxenaCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Kile D SmithDivision of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA.
Keli L HippenDivision of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA.
Christina PaluskieviczDepartment of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Marina WillsonshirkeyCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Bruce R BlazarDivision of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA.
Reza AbdiTransplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Jonathan S BrombergCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Electronic address: jbromberg@som.umaryland.edu.
University of Maryland, Baltimore · USMasonic Cancer CenterHarvard University · US

Funding

Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2M
Transgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SHARPE, ARLENE H. · 2003 to 2023
$42.5M
Project 3: Humoral Targets and B Cell Biology in Chronic Graft-vs.-Host DiseaseP01CA142106 · NCI · DANA-FARBER CANCER INST · PI CUTLER, COREY S · 2009 to 2019
$17.5M
Training Grant in Cancer BiologyT32CA154274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Toni M Antalis, CURT I CIVIN · 2011 to 2026
$6.8M
Enhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7M
Induction and Migration of Regulatory T Cells: Role of LymphotoxinR01AI062765 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BROMBERG, JONATHAN S · 2005 to 2019
$5.6M
T-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4M
In Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4M
GVL TO REDUCE AML RELAPSE AFTER MURINE ALLOGENEIC BMTR01CA072669 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1997 to 2017
$4.9M
Lymph Node Structure and Function in Tolerance: Role of LamininsR01AI114496 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BROMBERG, JONATHAN S · 2015 to 2024
$4.2M
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemiaR01HL147324 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Bruce R Blazar, HANS-PETER KIEM · 2020 to 2026
$4.1M
Regulatory T Cells and Lymphatic Endothelial Cells: Regulatory Interactions for Migration and SuppressionR37AI062765 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Jonathan S Bromberg · 2021 to 2026
$2.9M
NCI NIH HHS P01 CA065493NCI NIH HHS P01 CA142106NCI NIH HHS R01 CA072669NCI NIH HHS T32 CA154274NHLBI NIH HHS R01 HL056067NHLBI NIH HHS R01 HL118979NHLBI NIH HHS R01 HL141815NHLBI NIH HHS R01 HL145813NHLBI NIH HHS R01 HL147324NIAID NIH HHS P01 AI056299NIAID NIH HHS R01 AI062765NIAID NIH HHS R01 AI072039NIAID NIH HHS R01 AI114496NIAID NIH HHS R01 AI126596NIAID NIH HHS R37 AI034495NIAID NIH HHS R37 AI062765NIAID NIH HHS R56 AI041428NIAID NIH HHS R56 AI072039
6 · The paper itself

Abstract

Regulatory T cells (Tregs) express high levels of cell surface lymphotoxin alpha beta (LTα1β2) to activate the LT beta receptor (LTβR) on the lymphatic endothelial cells (LECs), modulating LEC adhesion molecules, intercellular junctions, and chemokines. We demonstrate a role for Tregs through this pathway to condition the permissiveness of lymphatic endothelia for transendothelial migration (TEM), thus gating leukocyte traffic. Human Tregs share the same property with murine Tregs. Activation of TLR2 on Tregs during inflammation specifically augments LTα1β2-LTβR signaling, which further enhances the permissiveness of LECs to facilitate TEM. The conditioning of endothelia may promote the resolution of inflammation by directing leukocytes out of tissues to lymphatic vessels and draining lymph nodes (dLNs). Thus, Tregs interact with lymphatic endothelia under homeostasis and inflammation and dictate endothelial permissiveness and gating mechanisms for subsequent leukocyte migration through endothelial barriers.

Indexed as

AnimalsCadherinsCD4-Positive T-LymphocytesCell LineCell MovementChemokine CCL21Endothelium, LymphaticHumansInflammationInterleukin-2Islets of LangerhansLymph NodesLymphotoxin beta ReceptorMAP Kinase Signaling SystemMiceMice, Inbred C57BLCadherinsChemokine CCL21Interleukin-2Ltbr protein, mouseLymphotoxin beta ReceptorNF-kappa BPcdh12 protein, mouseProtocadherinsReceptors, Interleukin-2Toll-Like Receptor 2Vascular Cell Adhesion Molecule-1lymphatic endothelial cellslymphotoxinregulatory T cellsToll-like receptor 2transendothelial migration

Identifiers

PMID31995749
PMCPMC7009789
OpenAlexW3003387389

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.